| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Etrasimod | Atopic dermatitis (AD) | Phase 2b | Oral | Immunology | |
| Pfizer Inc. | Olorinab | Irritable Bowel Syndrome | Phase 2b | Oral | Gastroenterology | |
| Pfizer Inc. | Taldefgrobep alfa | Obesity | Phase 2 | Ongoing | Intramuscular | Endocrinology |
| Pfizer Inc. | CRDF-004 | Metastatic colorectal cancer (mCRC) | Phase 2 | Data Released | Oral | Oncology |
| Pfizer Inc. | BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) - (PHAROS) | Advanced Lung Cancer | Phase 2 | Data Released | oral | Oncology |
| Pfizer Inc. | MET-233i + MET-097i | Obesity | Phase 2 | Ongoing | oral | Endocrinology |
| Pfizer Inc. | Disitamab vedotin plus toripalimab | HER2-expressing muscle-invasive bladder cancer (MIBC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Pfizer Inc. | Ponsegromab | Cancer-associated cachexia | Phase 2 | Trial Completed | Intravenous | Oncology |